<DOC>
	<DOCNO>NCT01485887</DOCNO>
	<brief_summary>This phase 3 , flexible-dose , open-label , multi-center study . The subject complete week 8 visit prior double-blind study ( B2411263 ) eligible participate study . This study consist 10 month treatment phase 1-3 week taper phase . The 2 follow-up visit evaluate 2 week 4 week last study medication dosing .</brief_summary>
	<brief_title>Venlafaxine ER Long-Term Extension Study Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Outpatients complete 8 week doubleblind study ( B2411263 ) , without major protocol violation tolerability concern opinion investigator . Clinically important abnormality baseline ( Week 8 doubleblind study ) physical examination , unresolved clinically significant abnormality electrocardiogram ( ECG ) , laboratory test result , vital sign record Week 8 previous doubleblind study . Significant risk suicide base clinical judgment . Use prohibit treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Venlafaxine ER</keyword>
	<keyword>long-term extension</keyword>
	<keyword>Japan</keyword>
</DOC>